On June 23, 2019, the Board of Directors of Pluristem Therapeutics Inc. approved the completion of the transition period of the Co-Chief Executive Officer structure and appointed Yaky Yanay to serve as the sole Chief Executive Officer of the Company, effective immediately. In addition, the Board of Directors of the Company and Mr. Zami Aberman mutually agreed that Mr. Aberman will cease to serve as Co-Chief Executive Officer of the Company and the Board of Directors appointed Mr. Aberman as the Executive Chairman of the Board of Directors of the Company, effective immediately.